AbbVie Reports meta-analysis Data for Semaglutide in Heart failure

AbbVie today announced meta-analysis results for semaglutide in patients with heart failure. The study demonstrated that semaglutide improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of heart failure and support the continued development of semaglutide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.